Humanwell Healthcare (600079) investor relations material

Executive summary

• Revenue for 2025 was ¥23.96 billion, down 5.79% year-over-year, mainly due to industry payment-side reforms and business structure optimization.

• Net profit attributable to shareholders rose 39.53% year-over-year to ¥1.86 billion; adjusted net profit (excluding non-recurring items) increased 54.75% to ¥1.76 billion.

• Main business gross margin improved to 48.21%, up 3.69 percentage points year-over-year.

• The company maintained leadership in anesthesia, steroid hormones, sexual health, and Uyghur medicine segments.

• R&D investment reached ¥1.68 billion, accounting for 6.99% of revenue, with over 2,000 R&D staff and 60+ innovative drug projects in the pipeline.

Financial highlights

• Operating income: ¥23.96 billion, down 5.79% year-over-year.

• Net profit attributable to shareholders: ¥1.86 billion, up 39.53% year-over-year.

• Adjusted net profit (excluding non-recurring items): ¥1.76 billion, up 54.75% year-over-year.

• Operating cash flow: ¥2.52 billion, up 16.38% year-over-year.

• Basic and diluted EPS: ¥1.14, up 39.02% year-over-year.

• Weighted average ROE: 10.16%, up 2.49 percentage points year-over-year.

• Proposed cash dividend: ¥4.80 per 10 shares, totaling ¥783 million, representing 42.23% of net profit.

Outlook and guidance

• 2026 revenue target set at over ¥24.5 billion, with gross margin above 48%.

• Focus on optimizing R&D resource allocation, accelerating innovative drug development, and expanding international business.

• Continued emphasis on cost control, asset quality improvement, and risk management.